[go: up one dir, main page]

RU98107643A - APPLICATION OF SUBSTITUTED PYRAZOLYL BENZENESULPHONAMIDES IN VETERINARIUM - Google Patents

APPLICATION OF SUBSTITUTED PYRAZOLYL BENZENESULPHONAMIDES IN VETERINARIUM

Info

Publication number
RU98107643A
RU98107643A RU98107643/13A RU98107643A RU98107643A RU 98107643 A RU98107643 A RU 98107643A RU 98107643/13 A RU98107643/13 A RU 98107643/13A RU 98107643 A RU98107643 A RU 98107643A RU 98107643 A RU98107643 A RU 98107643A
Authority
RU
Russia
Prior art keywords
benzenesulfonamide
pyrazol
aminocarbonyl
trifluoromethyl
cyano
Prior art date
Application number
RU98107643/13A
Other languages
Russian (ru)
Other versions
RU2253456C2 (en
Inventor
С.Исаксон Питер
Дж.Тэлли Джон
Original Assignee
Джи. Ди. Сирл Энд Ко.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/536,318 external-priority patent/US5756529A/en
Application filed by Джи. Ди. Сирл Энд Ко. filed Critical Джи. Ди. Сирл Энд Ко.
Publication of RU98107643A publication Critical patent/RU98107643A/en
Application granted granted Critical
Publication of RU2253456C2 publication Critical patent/RU2253456C2/en

Links

Claims (6)

1. Применение соединений формулы II:
Figure 00000001

где R2 выбран из гидридо, C1-C20-алкила, C1-C20-галогеналкила, C1-C10-алкоксикарбонила, циано, C1-C20-цианоалкила, карбоксила, аминокарбонила, C1-C20-алкиламинокарбонила, C3-C10-циклоалкиламинокарбонила, ариламинокарбонила, карбокси-C1-C20-алкиламинокарбонила, карбоксил-C1-C20-алкила,
арил-C1-C10-алкоксикарбонил-C1-C20-алкиламинокарбонила, аминокарбонил-C1-C20-алкила, C1-C10-алкоксикарбонилциано-C2-C20-алкенила и C1-C10-гидроксиалкила; где R3 выбран из гидридо, C1-C20-алкила, циано, C1-C6-гидроксиалкила, C3-C10-циклоалкила, C1-C20-алкилсульфонила и галогена; и где R4 выбран из арил-C2-C20-алкенила, арила, C3-C10-циклоалкила, C3-C10-циклоалкенила и гетероцикла; где R4 необязательно замещен в положении, способном к замещению, одним или нескольким радикалами, выбранными из галогена, C1-C10-алкилтио, C1-C20-алкилсульфонила, циано, нитро, C1-C20-галогеналкила, C1-C20-алкила, гидроксила, C2-C20-алкенила, C1-C10-гидроксиалкила, карбоксила, C3-C10-циклоалкила, C1-C20-алкиламино, C1-C20-диалкиламино, C1-C10-алкоксикарбонила, аминокарбонила, C1-C10-алкокси, C1-C10-галогеналкокси, сульфамила, гетероцикла и амино; или его фармацевтически приемлемой соли для получения лекарственного средства для лечения воспаления или связанного с воспалением заболевания у животного, выбранного из собак, кошек и лошадей.1. The use of compounds of formula II:
Figure 00000001

where R 2 is selected from hydrido, C 1 -C 20 alkyl, C 1 -C 20 haloalkyl, C 1 -C 10 alkoxycarbonyl, cyano, C 1 -C 20 cyanoalkyl, carboxyl, aminocarbonyl, C 1 -C 20 -alkylaminocarbonyl, C 3 -C 10 -cycloalkylaminocarbonyl, arylaminocarbonyl, carboxy-C 1 -C 20 -alkylaminocarbonyl, carboxyl-C 1 -C 20 -alkyl,
aryl-C 1 -C 10 -alkoxycarbonyl-C 1 -C 20 -alkylaminocarbonyl, aminocarbonyl-C 1 -C 20 -alkyl, C 1 -C 10 -alkoxycarbonylcyano-C 2 -C 20 -alkenyl and C 1 -C 10 - hydroxyalkyl; where R 3 is selected from hydrido, C 1 -C 20 alkyl, cyano, C 1 -C 6 hydroxyalkyl, C 3 -C 10 cycloalkyl, C 1 -C 20 alkylsulfonyl and halogen; and where R 4 is selected from aryl-C 2 -C 20 alkenyl, aryl, C 3 -C 10 cycloalkyl, C 3 -C 10 cycloalkenyl and heterocycle; where R 4 is optionally substituted at the position capable of substitution with one or more radicals selected from halogen, C 1 -C 10 -alkylthio, C 1 -C 20 -alkylsulfonyl, cyano, nitro, C 1 -C 20 -haloalkyl, C 1 -C 20 alkyl, hydroxyl, C 2 -C 20 alkenyl, C 1 -C 10 hydroxyalkyl, carboxyl, C 3 -C 10 cycloalkyl, C 1 -C 20 alkylamino, C 1 -C 20 dialkylamino C 1 -C 10 alkoxycarbonyl, aminocarbonyl, C 1 -C 10 alkoxy, C 1 -C 10 haloalkoxy, sulfamyl, heterocycle and amino; or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of inflammation or an inflammation-related disease in an animal selected from dogs, cats and horses. 2. Применение по п.1, где R2 выбран из гидридо, C1-C10-алкила, C1-C6-галогеналкила, C1-C6-алкоксикарбонила, циано, C1-C10-цианоалкила, карбоксила, аминокарбонила, C1-C10-алкиламинокарбонила, C3-C7-циклоалкиламинокарбонила, ариламинокарбонила, карбокси-C1-C10-алкиламинокарбонила, арил-C1-C6-алкоксикарбонил-C1-C10-алкиламинокарбонила, аминокарбонил-C1-C10-алкила, C1-C10-карбоксиалкила, C1-C6-алкоксикарбонилциано-C2-C6-алкенила и C1-C6-гидроксиалкила; где R3 выбран из гидридо, C1-C10-алкила, циано, C1-C6-гидроксиалкила, C3-C7-циклоалкила, C1-C6-алкилсульфонила и галогена; и где R4 выбран из арил-C2-C20-алкенила, арила, C3-C10-циклоалкила, C3-C10-циклоалкенила и гетероцикла; где R4 необязательно замещен в положении, способном к замещению, одним или несколькими радикалами, выбранными из галогена, C1-C10-алкилтио, C1-C6-алкилсульфонила, циано, нитро, C1-C6-галогеналкила, C1-C10-алкила, гидроксила, C2-C6-алкенила, C1-C6-гидроксиалкила, карбоксила, C3-C7-циклоалкила, C1-C6-алкиламино, C1-C6-диалкиламино, C1-C6-алкоксикарбонила, аминокарбонила, C1-C6-алкокси,
C1-C6-галогеналкокси, сульфамила, пяти- или шестичленного гетероцикла и амино; или его фармацевтически приемлемой соли.2. The use according to claim 1, where R 2 selected from hydrido, C 1 -C 10 -alkyl, C 1 -C 6 -haloalkyl, C 1 -C 6 -alkoxycarbonyl, cyano, C 1 -C 10 -cyanoalkyl, carboxyl , aminocarbonyl, C 1 -C 10 -alkylaminocarbonyl, C 3 -C 7 -cycloalkylaminocarbonyl, arylaminocarbonyl, carboxy-C 1 -C 10 -alkylaminocarbonyl, aryl-C 1 -C 6 -alkoxycarbonyl-C 1 -C 10 -alkylaminocarbonyl, aminocarbon -C 1 -C 10 alkyl, C 1 -C 10 carboxyalkyl, C 1 -C 6 alkoxycarbonylcyano-C 2 -C 6 alkenyl and C 1 -C 6 hydroxyalkyl; wherein R 3 is selected from hydrido, C 1 -C 10 alkyl, cyano, C 1 -C 6 hydroxyalkyl, C 3 -C 7 cycloalkyl, C 1 -C 6 alkylsulfonyl and halogen; and where R 4 is selected from aryl-C 2 -C 20 alkenyl, aryl, C 3 -C 10 cycloalkyl, C 3 -C 10 cycloalkenyl and heterocycle; where R 4 is optionally substituted in a position capable of substitution with one or more radicals selected from halogen, C 1 -C 10 alkylthio, C 1 -C 6 alkylsulfonyl, cyano, nitro, C 1 -C 6 haloalkyl, C 1 -C 10 -alkyl, hydroxyl, C 2 -C 6 -alkenyl, C 1 -C 6 -hydroxyalkyl, carboxyl, C 3 -C 7 -cycloalkyl, C 1 -C 6 -alkylamino, C 1 -C 6 -alkylamino , C 1 -C 6 alkoxycarbonyl, aminocarbonyl, C 1 -C 6 alkoxy,
C 1 -C 6 haloalkoxy, sulfamyl, five- or six-membered heterocycle, and amino; or a pharmaceutically acceptable salt thereof. 3. Применение по п.2, где соединение выбирают из соединений и их фармацевтически приемлемых солей группы, состоящей из 4-[5-(4-хлорфенил)-3-(трифторметил)-1Н-пиразол-1-ил]бензолсульфонамида; 4-[5-фенил-3-(трифторметил)-1Н-пиразол-1-ил] бензолсульфонамида; 4-[5-(4-фторфенил)-3-(трифторметил)-1Н-пиразол-1-ил] бензолсульфонамида; 4-[5-(4-метоксифенил)-3-(трифторметил)-1Н-пиразол-1-ил] бензолсульфонамида; 4-[5-(4-хлорфенил)-3-(трифторметил)-1Н-пиразол-1-ил] бензолсульфонамида; 4-[5-(4-метилфенил)-3-(трифторметил)-1Н-пиразол-1-ил] бензолсульфонамида; 4-[4-хлор-5-(4-хлорфенил)-3-(трифторметил)-1Н-пиразол-1-ил]бензолсульфонамида; 4-[3-(дифторметил)-5-(4-метилфенил)-1Н-пиразол-1-ил] бензолсульфонамида; 4-[3-(дифторметил)-5-фенил-1Н-пиразол-1-ил]бензолсульфонамида; 4-[3-(дифторметил)-5-(4-метоксифенил)-1Н-пиразол-1-ил] бензолсульфонамида; 4-[3-циано-5-(4-фторфенил)-1Н-пиразол-1-ил]бензолсульфонамида; 4-[3-(дифторметил)-5-(3-фтор-4-метоксифенил)-1Н-пиразол-1-ил] бензолсульфонамида; 4-[4-(3-фтор-4-метоксифенил)-3-(трифторметил)-1Н-пиразол-1-ил] бензолсульфонамида; 4-[4-хлор-5-фенил-1Н-пиразол-1-ил] бензолсульфонамида; 4-[5-(4-хорфенил)-3-(гидроксиметил)-1Н-пиразол-1-ил] бензолсульфонамида и 4-[5-(4-N,N-диметиламино)фенил)-3-(трифторметил)-1Н-пиразол-1-ил]бензолсульфонамида. 3. The use according to claim 2, where the compound is selected from compounds and their pharmaceutically acceptable salts of the group consisting of 4- [5- (4-chlorophenyl) -3- (trifluoromethyl) -1H-pyrazol-1-yl] benzenesulfonamide; 4- [5-phenyl-3- (trifluoromethyl) -1H-pyrazol-1-yl] benzenesulfonamide; 4- [5- (4-fluorophenyl) -3- (trifluoromethyl) -1H-pyrazol-1-yl] benzenesulfonamide; 4- [5- (4-methoxyphenyl) -3- (trifluoromethyl) -1H-pyrazol-1-yl] benzenesulfonamide; 4- [5- (4-chlorophenyl) -3- (trifluoromethyl) -1H-pyrazol-1-yl] benzenesulfonamide; 4- [5- (4-methylphenyl) -3- (trifluoromethyl) -1H-pyrazol-1-yl] benzenesulfonamide; 4- [4-chloro-5- (4-chlorophenyl) -3- (trifluoromethyl) -1H-pyrazol-1-yl] benzenesulfonamide; 4- [3- (difluoromethyl) -5- (4-methylphenyl) -1H-pyrazol-1-yl] benzenesulfonamide; 4- [3- (difluoromethyl) -5-phenyl-1H-pyrazol-1-yl] benzenesulfonamide; 4- [3- (difluoromethyl) -5- (4-methoxyphenyl) -1H-pyrazol-1-yl] benzenesulfonamide; 4- [3-cyano-5- (4-fluorophenyl) -1H-pyrazol-1-yl] benzenesulfonamide; 4- [3- (difluoromethyl) -5- (3-fluoro-4-methoxyphenyl) -1H-pyrazol-1-yl] benzenesulfonamide; 4- [4- (3-fluoro-4-methoxyphenyl) -3- (trifluoromethyl) -1H-pyrazol-1-yl] benzenesulfonamide; 4- [4-chloro-5-phenyl-1H-pyrazol-1-yl] benzenesulfonamide; 4- [5- (4-chorophenyl) -3- (hydroxymethyl) -1H-pyrazol-1-yl] benzenesulfonamide and 4- [5- (4-N, N-dimethylamino) phenyl) -3- (trifluoromethyl) - 1H-pyrazol-1-yl] benzenesulfonamide. 4. Применение по п.1 для лечения воспаления. 4. The use according to claim 1 for the treatment of inflammation. 5. Применение по п.1 для лечения связанного с воспалением заболевания. 5. The use according to claim 1 for the treatment of inflammation-related diseases. 6. Применение по п.2, где R2 выбран из гидридо, метила, этила, изопропила, трет-бутила, изобутила, гексила, фторметила, дифторметила, трифторметила, хлорметила, дихлорметила, трихлорметила, пентафторэтила, гептафторпропила, дифторхлорметила, дихлорфторметила, дифторэтила, дифторпропила, дихлорэтила, дихлорпропила, циано, карбоксила, метоксикарбонила, этоксикарбонила, изопропоксикарбонила, трет-бутоксикарбонила, пропоксикарбонила, бутоксикарбонила, изобутоксикарбонила, пентоксикарбонила, ацетила, пропионила, бутирила, изобутирила, валерила, изовалерила, пивалоила, гексаноила, трифторацетила, цианометила, этоксикарбонилцианоэтенила, аминокарбонила, аминокарбонилметила, N-метиламинокарбонила, N-этиламинокарбонила, N-изопропиламинокарбонила, N-пропиламинокарбонила, N-бутиламинокарбонила, N-изобутиламинокарбонила, N-трет-бутиламинокарбонила, N-пентиламинокарбонила, N-фениламинокарбонила, N,N-диметиламинокарбонила, N-метил-N-этиламинокарбонила, N-(3-фторфенил)аминокарбонила, N-(4-метилфенил)аминокарбонила, N-(3-хлорфенил)аминокарбонила, N-метил-N-(3-хлорфенил)аминокарбонила, N-(4-метоксифенил)аминокарбонила, N-метил-N-фениламинокарбонила, циклопентиламинокарбонила, циклогексиламинокарбонила, карбоксиметиламинокарбонила, бензилоксикарбонилметиламинокарбонила, гидроксипропила, гидроксиметила и гидроксипропила; где R3 выбран из гидридо, метила, этила, изопропила, трет-бутила, изобутила, гексила, фтора, хлора, брома, циано, метилсульфонила, циклопропила, циклопентила, гидроксипропила, гидроксиметила и гидроксиэтила; где R4 выбран из фенилэтенила, фенила, нафтила, бифенила, циклогексила, циклопентила, циклогептила, 1-циклогексенила, 2-циклогексенила, 3-циклогексенила, 4-циклогексенила, 1-циклопентенила, 4-циклопентенила, бензофурила, 2,3-дигидробензофурила, 1,2,3,4-тетрагидронафтила, бензотиенила, инденила, инданила, индолила, дигидроиндолила, хроманила, бензопирана, тиохроманила, бензотиопирана, бензодиоксолила, бензодиоксанила, пиридила, тиенила, тиазолила, оксазолила, фурила и пиразинила; где R4 необязательно замещен в положении, способном к замещению, одним или несколькими радикалами, выбранными из фтора, хлора, брома, метилтио, метила, этила, пропила, изопропила, трет-бутила, изобутила, гексила, этиленила, пропенила, метилсульфонила, циано, карбоксила, метоксикарбонила, этоксикарбонила, изопропоксикарбонила, трет-бутоксикарбонила, пропоксикарбонила, бутоксикарбонила, изобутоксикарбонила, пентоксикарбонила, аминокарбонила, фторметила, дифторметила, трифторметила, хлорметила, дихлорметила, трихлорметила, пентафторэтила, гептафторпропила, бромдифторметила, дифторхлорметила, дихлорфторметила, дифторэтила, дифторпропила, дихлорэтила, дихлорпропила, гидроксила, метокси, метилендиокси, этокси, пропокси, н-бутокси, сульфамила, гидроксипропила, гидроксиизопропила, гидроксиметила, гидроксиэтила, трифторметокси, N-метиламино, N-этиламино, N-этил-N-метиламино, N, N-диметиламино, N,N-диэтиламино, амино, пиперадинила, пиперазинила, морфолино и нитро; или фармацевтически приемлемой его соли.6. The use according to claim 2, where R 2 is selected from hydrido, methyl, ethyl, isopropyl, tert-butyl, isobutyl, hexyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochlorofluoromethyl, , difluoropropyl, dichloroethyl, dichloropropyl, cyano, carboxyl, methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl, tert-butoxycarbonyl, propoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, pentoxycarbonyl, acetyl, propionyl, butyryl, isobutyl, isobutyr a, isovaleryl, pivaloyl, hexanoyl, trifluoroacetyl, cyanomethyl, ethoxycarbonylcyanoethenyl, aminocarbonyl, aminocarbonylmethyl, N-methylaminocarbonyl, N-ethylaminocarbonyl, N-isopropylaminocarbonylamino-N-butylamino-carbonyl, N-propylaminocarbonylamino-butylamino-butylcarbonyl, N-butylcarbonyl, N-butylcarbonyl, N-butyl pentylaminocarbonyl, N-phenylaminocarbonyl, N, N-dimethylaminocarbonyl, N-methyl-N-ethylaminocarbonyl, N- (3-fluorophenyl) aminocarbonyl, N- (4-methylphenyl) aminocarbonyl, N- (3-chlorophenyl) aminocarbonyl, N-methyl -N- (3-chlorophenyl) aminocarbonyl, N- (4-methoxy iphenyl) aminocarbonyl, N-methyl-N-phenylaminocarbonyl, cyclopentylaminocarbonyl, cyclohexylaminocarbonyl, carboxymethylaminocarbonyl, benzyloxycarbonylmethylaminocarbonyl, hydroxypropyl, hydroxymethyl and hydroxypropyl; where R 3 selected from hydrido, methyl, ethyl, isopropyl, tert-butyl, isobutyl, hexyl, fluorine, chlorine, bromine, cyano, methylsulfonyl, cyclopropyl, cyclopentyl, hydroxypropyl, hydroxymethyl and hydroxyethyl; where R 4 is selected from phenylethenyl, phenyl, naphthyl, biphenyl, cyclohexyl, cyclopentyl, cycloheptyl, 1-cyclohexenyl, 2-cyclohexenyl, 3-cyclohexenyl, 4-cyclohexenyl, 1-cyclopentenyl, 4-cyclopentenyl, benzofuryl, 2,3-dig 1,2,3,4-tetrahydronaphthyl, benzothienyl, indenyl, indanyl, indolyl, dihydroindolyl, chromanyl, benzopyran, thiochromanil, benzothiopyran, benzodioxolyl, benzodioxanil, pyridyl, thienyl, thiazolyl, oxazolyl, furyl and pyrazinyl; where R 4 is optionally substituted in a position capable of substitution with one or more radicals selected from fluorine, chlorine, bromine, methylthio, methyl, ethyl, propyl, isopropyl, tert-butyl, isobutyl, hexyl, ethylenyl, propenyl, methylsulfonyl, cyano , carboxyl, methoxycarbonyl, ethoxycarbonyl, isopropoxycarbonyl, tert-butoxycarbonyl, propoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, pentoxycarbonyl, aminocarbonyl, fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, trichloromethyl, trichloromethyl heptafluoropropyl, bromodifluoromethyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl, dichloropropyl, hydroxyl, methoxy, methylenedioxy, ethoxy, propoxy, n-butoxy, sulfamyl, hydroxypropyl, hydroxyethylmethymethiopropylmethyl, hydroxyethylmethiopropyl, hydroxyethylmethiopropyl, hydroxyethylmethiopropyl, hydroxyethylmethiopropyl, hydroxyethylmethyl, hydroxyethylmethyl N-ethyl-N-methylamino, N, N-dimethylamino, N, N-diethylamino, amino, piperadinyl, piperazinyl, morpholino and nitro; or a pharmaceutically acceptable salt thereof.
RU98107643/13A 1995-09-29 1996-09-27 Method for treating inflammation or inflammation-induced disease in dogs RU2253456C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/536,318 US5756529A (en) 1995-09-29 1995-09-29 Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies
US08/536,318 1995-09-29

Publications (2)

Publication Number Publication Date
RU98107643A true RU98107643A (en) 2000-02-20
RU2253456C2 RU2253456C2 (en) 2005-06-10

Family

ID=24138015

Family Applications (1)

Application Number Title Priority Date Filing Date
RU98107643/13A RU2253456C2 (en) 1995-09-29 1996-09-27 Method for treating inflammation or inflammation-induced disease in dogs

Country Status (21)

Country Link
US (1) US5756529A (en)
EP (1) EP0854723B1 (en)
JP (1) JPH11514991A (en)
KR (1) KR100498730B1 (en)
CN (1) CN1202828A (en)
AT (1) ATE238058T1 (en)
AU (1) AU718300B2 (en)
BR (1) BR9610974A (en)
CA (1) CA2233620C (en)
CZ (1) CZ297183B6 (en)
DE (1) DE69627683T2 (en)
DK (1) DK0854723T3 (en)
ES (1) ES2197954T3 (en)
IL (1) IL123635A (en)
NO (1) NO321157B1 (en)
NZ (1) NZ320919A (en)
PL (1) PL191934B1 (en)
PT (1) PT854723E (en)
RO (1) RO120408B1 (en)
RU (1) RU2253456C2 (en)
WO (1) WO1997011704A1 (en)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492411B1 (en) * 1993-11-30 2002-12-10 G. D. Searle & Co. Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation
EP0828718A1 (en) 1995-06-02 1998-03-18 G.D. SEARLE & CO. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US6514977B1 (en) * 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
AU7726898A (en) * 1997-05-22 1998-12-11 G.D. Searle & Co. Pyrazole derivatives as p38 kinase inhibitors
US6979686B1 (en) 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
US6294558B1 (en) 1999-05-31 2001-09-25 Pfizer Inc. Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
US6727238B2 (en) * 1998-06-11 2004-04-27 Pfizer Inc. Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
TNSN99111A1 (en) * 1998-06-11 2005-11-10 Pfizer NOVEL SULFONYLBENZENE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
SA99191255B1 (en) * 1998-11-30 2006-11-25 جي دي سيرل اند كو celecoxib compounds
DE60023119T2 (en) * 1999-03-10 2006-07-20 G.D. Searle Llc COMPOSITIONS FOR THE ADMINISTRATION OF A CYCLOOXYGENASE-2 HEMMER TO ANIMALS
CA2377153A1 (en) 1999-06-16 2000-12-21 Temple University - Of The Commonwealth System Of Higher Education 1-(4-sulfamylaryl)-3-substituted-5-aryl-2-pyrazolines as inhibitors of cyclooxygenase-2
ES2208227T3 (en) * 1999-12-03 2004-06-16 Pfizer Products Inc. HETEROARILFENILPIRAZOL COMPOUNDS AS ANTI-INFLAMMATORY / ANALGESIC AGENTS.
ATE291019T1 (en) 1999-12-03 2005-04-15 Pfizer Prod Inc HETEROCYCLO-ALKYLSULFONYLPYRAZOLE DERIVATIVES FOR USE AS ANTI-IMFLAMMATORY OR ANALGESIC COMPOUNDS
EP1104758B1 (en) * 1999-12-03 2003-07-23 Pfizer Products Inc. Acetylene derivatives as anti-inflammatory/analgesic agents
PT1104760E (en) 1999-12-03 2003-06-30 Pfizer Prod Inc SULFAMOYL-HETEROARILPIRAZOLE COMPOUNDS AS ANALGESIC AND ANTI-INFLAMMATORY AGENTS
PT1150960E (en) * 1999-12-08 2005-06-30 Pharmacia Corp CELECOXIB POLYMORIC CRYSTALLINE FORMS
DE60016191T2 (en) * 1999-12-08 2005-12-22 Pharmacia Corp., Chicago CYCLOOXYGENASE-2 INHIBITORY COMPOSITIONS WITH FAST ACTION INTRUSION
BR0016705A (en) * 1999-12-22 2002-09-24 Pharmacia Corp Dual-release compositions of a cyclooxygenase-2 inhibitor
AU2001253418A1 (en) * 2000-04-12 2001-10-30 Smith Kline Beecham Corporation Compounds and methods
AU2001251650A1 (en) * 2000-04-18 2001-10-30 Pharmacia Corporation Rapid-onset formulation of a selective cyclooxigenase-2
AU2001253749A1 (en) * 2000-04-25 2001-11-07 Pharmacia Corporation 2-fluorobenzenesulfonyl compounds for the treatment of inflammation
PE20020146A1 (en) * 2000-07-13 2002-03-31 Upjohn Co OPHTHALMIC FORMULATION INCLUDING A CYCLOOXYGENASE-2 (COX-2) INHIBITOR
US20030219461A1 (en) * 2000-09-12 2003-11-27 Britten Nancy J. Parenteral combination therapy for infective conditions
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
MY137736A (en) 2001-04-03 2009-03-31 Pharmacia Corp Reconstitutable parenteral composition
US6673818B2 (en) 2001-04-20 2004-01-06 Pharmacia Corporation Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation
ATE298749T1 (en) 2001-07-05 2005-07-15 Pfizer Prod Inc HETEROCYCLO-ALKYLSULFONYL PYRAZOLES AS ANTI-INFLAMMATORY/ANALGESIC AGENTS
US7076539B2 (en) * 2001-07-30 2006-07-11 Hewlett-Packard Development Company, L.P. Network connectivity establishment at user log-in
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
ES2286275T3 (en) 2001-09-19 2007-12-01 Pharmacia Corporation PIRAZOLO COMPOUNDS REPLACED FOR THE TREATMENT OF INFLAMMATION.
AU2002341729A1 (en) 2001-09-19 2003-04-01 Pharmacia Corporation Substituted pyrazolyl compounds for the treatment of inflammation
GT200200183A (en) 2001-09-28 2003-05-23 PROCEDURE TO PREPARE DERIVATIVES OF HETEROCICLOALQUILSULFONIL PIRAZOL
WO2003037351A1 (en) 2001-11-02 2003-05-08 Pfizer Products Inc. Heterocyclo-alkylsulfonyl pyrazoles and their use as cox-2 inhibitors
WO2003037330A1 (en) 2001-11-02 2003-05-08 Pfizer Products Inc. Sulfonyl-and sulfonylheteroaryl-pyrazoles with a hydrazinyl or nitrogen oxide substituent at the 5-position for use as cyclooxygenase inhibitors
EP1440062A1 (en) 2001-11-02 2004-07-28 Pfizer Products Inc. An efficient synthesis of 5-heteroatom-containing-pyrazoles
WO2003037335A1 (en) * 2001-11-02 2003-05-08 Pfizer Products Inc. 5-heteroatom-substituted pyrazoles
EP1499597A4 (en) * 2002-04-08 2006-01-25 Univ Ohio State Res Found COMPOUNDS AND METHOD FOR INDUCING APOPTOSIS IN PROLIFERATING CELLS
WO2004002420A2 (en) 2002-06-28 2004-01-08 Nitromed, Inc. Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxigenase-2 selective inhibitors, compositions and methods of use
UA79804C2 (en) 2002-07-03 2007-07-25 Janssen Pharmaceutica Nv Cck-1 receptor modulators
US8455458B2 (en) 2002-10-16 2013-06-04 Arthrodynamic Technologies, Animal Health Division, Inc. Composition and method for treating connective tissue damage
US7803787B2 (en) * 2002-10-16 2010-09-28 Arthrodynamic Technologies, Animal Health Division, Inc. Composition and method for treating connective tissue damage by transmucosal administration
US20080003258A1 (en) * 2002-10-16 2008-01-03 Marcum Frank D Composition and Method for Treating Rheumatoid Arthritis
US20080153894A1 (en) * 2002-12-19 2008-06-26 Pharmacia Corporation Cyclooxygenase-2 inhibitor and antibacterial agent combination for intramammary treatment of mastitis
US20050009931A1 (en) * 2003-03-20 2005-01-13 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
US20040214753A1 (en) * 2003-03-20 2004-10-28 Britten Nancy Jean Dispersible pharmaceutical composition for treatment of mastitis and otic disorders
US20050004098A1 (en) * 2003-03-20 2005-01-06 Britten Nancy Jean Dispersible formulation of an anti-inflammatory agent
PT1608407E (en) * 2003-03-20 2006-12-29 Pharmacia Corp Dispersible formulation of an anti-inflammatory agent
EP1534305B9 (en) 2003-05-07 2007-03-07 Osteologix A/S Treating cartilage / bone conditions with water-soluble strontium salts
US20050131028A1 (en) * 2003-09-11 2005-06-16 Pharmacia Corporation Methods and compositions for the extended duration treatment of pain, inflammation and inflammation-related disorders
US7659426B2 (en) * 2003-12-01 2010-02-09 Reverse Proteomics Research Institute Co., Ltd. Target protein of anticancer agent and novel anticancer agent (spnal) corresponding thereto
US7250434B2 (en) 2003-12-22 2007-07-31 Janssen Pharmaceutica N.V. CCK-1 receptor modulators
ITMI20041032A1 (en) * 2004-05-24 2004-08-24 Neuroscienze S C A R L PHARMACEUTICAL COMPOSITES
US7923465B2 (en) 2005-06-02 2011-04-12 Glenmark Pharmaceuticals S.A. Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
US8128460B2 (en) * 2006-09-14 2012-03-06 The Material Works, Ltd. Method of producing rust inhibitive sheet metal through scale removal with a slurry blasting descaling cell
MX2009008165A (en) * 2007-02-01 2009-08-12 Iams Company Method for decreasing inflammation and oxidative stress in mammals.
TW200911240A (en) * 2007-06-11 2009-03-16 Kyowa Hakko Kogyo Kk Anti-tumor agent
US9186375B2 (en) 2007-06-21 2015-11-17 Arthrodynamic Technologies, Animal Health Division, Inc. Glycosaminoglycan compositions in combination with stem cells
RU2406505C2 (en) * 2007-06-29 2010-12-20 Федеральное государственное образовательное учреждение высшего профессионального образования "САНКТ-ПЕТЕРБУРГСКАЯ ГОСУДАРСТВЕННАЯ АКАДЕМИЯ ВЕТЕРИНАРНОЙ МЕДИЦИНЫ" (ФГОУ ВПО СПГАВМ) Method of treating inflammatory disease of metacarpus and metatarsus in dogs
RU2639876C2 (en) 2010-03-30 2017-12-25 Версеон Корпорейшн Multi-substituted aromatic compounds as thrombin inhibitors
AU2012213086B2 (en) * 2011-02-03 2016-05-05 Lupin Limited Pyrrole derivatives used as modulators of alpha7 nAChR
CN103242233B (en) * 2012-02-08 2014-07-30 北京博爱汇康医药科技有限责任公司 Novel method for preparing celecoxib
WO2014012074A2 (en) * 2012-07-12 2014-01-16 Euclises Pharmaceuticals, Inc. No-releasing nonoate (nitrogen-bound) sulfonamide-linked-coxib anti-cancer agents
MX373964B (en) 2013-03-15 2020-07-13 Verseon Corp MULTI-SUBSTITUTED AROMATIC COMPOUNDS AS SERINE PROTEASE INHIBITORS.
US9951025B2 (en) 2013-03-15 2018-04-24 Verseon Corporation Halogenopyrazoles as inhibitors of thrombin
EP2886104A1 (en) 2013-12-11 2015-06-24 Patir, Suleyman An intra-articular gel
US10189810B2 (en) 2014-09-17 2019-01-29 Verseon Corporation Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
SI3261639T1 (en) 2015-02-27 2023-01-31 Verseon International Corporation Substituted pyrazole compounds as serine protease inhibitors
CN107686465B (en) * 2017-09-02 2020-10-27 东北农业大学 Preparation method of deracoxib
WO2020163689A1 (en) 2019-02-08 2020-08-13 University Of Pittsburgh - Of The Commonwealth System Of Higher Education 20-hete formation inhibitors
CN114292235B (en) * 2021-12-29 2023-04-14 江苏天和制药有限公司 A kind of preparation and purification method of deracoxib

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940418A (en) * 1972-04-07 1976-02-24 G. D. Searle & Co. Esters and amides of 4,5-dihydrobenz[g]indazole-3-carboxylic acids and related compounds
GB8814587D0 (en) * 1988-06-20 1988-07-27 Erba Carlo Spa Condensed pyrazole 3-oxo-propanenitrile derivatives & process for their preparation
PH27357A (en) * 1989-09-22 1993-06-21 Fujisawa Pharmaceutical Co Pyrazole derivatives and pharmaceutical compositions comprising the same
FR2665898B1 (en) * 1990-08-20 1994-03-11 Sanofi DERIVATIVES OF AMIDO-3 PYRAZOLE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US5134155A (en) * 1991-08-08 1992-07-28 Ortho Pharmaceutical Corporation Tetrahydroindazole, tetrahydrocyclopentapyrazole, and hexahydrocycloheptapyrazole compounds and their use as HMG-coA reductase inhibitors
IL104311A (en) * 1992-02-05 1997-07-13 Fujisawa Pharmaceutical Co Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5401765A (en) * 1993-11-30 1995-03-28 G. D. Searle 1,4,5-triphenyl pyrazolyl compounds for the treatment of inflammation and inflammation-related disorders
NZ276885A (en) * 1993-11-30 1999-08-30 Searle & Co Substituted pyrazolyl-benzenesulphonamide derivatives, preparation and pharmaceutical compositions thereof
US5434178A (en) * 1993-11-30 1995-07-18 G.D. Searle & Co. 1,3,5 trisubstituted pyrazole compounds for treatment of inflammation
US5475018A (en) * 1993-11-30 1995-12-12 G. D. Searle & Co. 1,5-diphenyl pyrazole compounds for treatment of inflammation

Similar Documents

Publication Publication Date Title
RU98107643A (en) APPLICATION OF SUBSTITUTED PYRAZOLYL BENZENESULPHONAMIDES IN VETERINARIUM
CA2233620A1 (en) Substituted pyrazolyl benzenesulfonamides for use in veterinary therapies as antiinflammatory agents
RU96115039A (en) PYRAZOLYL SUBSTITUTED BENZENOSULPHONAMIDES FOR THE TREATMENT OF INFLAMMATION
JP2021011495A5 (en)
KR940021533A (en) Benzimidazole Compounds, Their Uses and Methods of Preparation
CA2151674C (en) Methods of administering crf antagonists
US8410272B2 (en) Pyrazolylbenzothiazole derivatives and their use as therapeutic agents
JP2003528872A5 (en)
JP2007500226A5 (en)
RU2003130648A (en) DIHYDROBENZO DERIVATIVES [B] [1,4] DIAZEPIN-2-ONE AS 1MGIUR2 ANTAGONISTS
JP2001517652A5 (en)
DE59713007D1 (en) NEW HETEROCYCLYLMETHYL-SUBSTITUTED PYRAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF HEART CIRCULATION DISEASES
RU2006129297A (en) N- (1,5-DIPHENYL-1H-PYRAZOL-3-YL) SULFONAMIDE DERIVATIVES WITH an affinity for CB1 receptors
JP2003511384A5 (en)
RU98115659A (en) SULFURED AMINO ACID DERIVATIVES AND METALLOPROTEINASE INHIBITORS CONTAINING THEM
KR900001694A (en) Compounds
WO2004045509A2 (en) Method of using a cox-2 inhibitor and a 5-ht1a receptor modulator as a combination therapy
AU2003207557A1 (en) Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
RU2005121897A (en) AMINOINDAZOLE DERIVATIVES AND THEIR APPLICATION AS KINAZ INHIBITORS
RU97121308A (en) METHOD OF OBTAINING 3-HALOGENALKYL-1H-PYRAZOLES
IL269710B2 (en) 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers
RU2005109912A (en) Phenyl-indole compounds for modulating IGE and suppressing cell growth
RU2002119016A (en) N- [5 - [[[5-alkyl-2-oxazolyl] methyl] thio] -2-thiazolyl] carboxamide inhibitors of cyclin-dependent kinases
MXPA06004657A (en) COMBINATIONS COMPRISING AN Hsp90 INHIBITOR AND A PHOPHODIESTERASE INHIBITOR FOR TREATING OR PREVENTING NEOPLASIA.
RU2004119957A (en) HYDRAZONPYRAZOL DERIVATIVES AND THEIR APPLICATION AS A MEDICINAL PRODUCT